Brokers Offer Predictions for Edesa Biotech FY2028 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Research analysts at Zacks Small Cap issued their FY2028 earnings estimates for shares of Edesa Biotech in a note issued to investors on Monday, December 15th. Zacks Small Cap analyst D. Bautz anticipates that the company will earn ($0.55) per share for the year. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Edesa Biotech (NASDAQ:EDSA) last announced its earnings results on Friday, December 12th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.80. The firm had revenue of $0.25 million for the quarter.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Edesa Biotech in a research report on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Edesa Biotech in a report on Monday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.00.

Edesa Biotech Stock Performance

EDSA opened at $1.49 on Tuesday. The company has a market capitalization of $12.37 million, a PE ratio of -1.10 and a beta of 0.08. The stock’s fifty day moving average is $1.98 and its 200-day moving average is $2.16. Edesa Biotech has a one year low of $1.44 and a one year high of $4.49.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in EDSA. Velan Capital Investment Management LP purchased a new stake in shares of Edesa Biotech in the 1st quarter valued at approximately $1,678,000. Stonepine Capital Management LLC purchased a new position in Edesa Biotech during the 1st quarter worth approximately $1,678,000. Nantahala Capital Management LLC acquired a new stake in Edesa Biotech during the 1st quarter valued at $1,525,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Edesa Biotech in the third quarter valued at $36,000. 5.50% of the stock is owned by hedge funds and other institutional investors.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.